Methods for the treatment of a cancer or fibrotic disorder associated with MENA or MENA(INV) by administering a map kinase inhibitor

Abstract

Phosphorylation and dephosphorylation of MENA and MENA isoforms regulates the metastatic activity of cancer cells. Administration of a MENA kinase inhibitor results in significant reduction in the development of cancer metastasis in established and developing tumors. Administration of a MENA kinase inhibitor in conjunction with a tyrosine kinase inhibitor enhances efficacy of tyrosine kinase inhibitor therapy. Administration of a MENA kinase inhibitor in conjunction with anti-microtubule agent results in significant reduction in chemotherapy-induced tumor cell dissemination and enhances efficacy of anti-microtubule therapy.

Claims

1. A method for the treatment of a cancer or fibrotic disorder associated with elevated MENA protein (SEQ ID NO: 1) and/or MENA.sup.INV protein (SEQ ID NO: 3) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a protein kinase inhibitor that inhibits phosphorylation of a serine residue on a MENA isoform substrate, selected from at least one of MENA protein (SEQ ID NO: 1) or MENA.sup.INV protein (SEQ ID NO: 3), wherein the protein kinase inhibitor inhibits the transfer of phosphate to Ser125 of SEQ ID NO:1 and/or inhibits the transfer of phosphate to Ser144 of SEQ ID NO:3 and wherein the protein kinase inhibitor inhibits a MAP kinase signaling pathway.

2. The method according to claim 1, wherein the protein kinase inhibitor is at least one of a MAPKAPK2/MK2 inhibitor, p38 MAPK inhibitor, and MEK inhibitor.

3. The method according to claim 2, wherein the protein kinase inhibitor is a MAPKAPK2/MK2 inhibitor.

4. The method according to claim 1, wherein the protein kinase inhibitor is administered to the subject orally, intravenously, intramuscularly, intraperitoneally, intrapulmonarily, intratumorally, intranasally, intrathecally or subcutaneously.

5. The method according to claim 1, wherein the protein kinase inhibitor is co-administered to the subject with another therapeutic agent.

6. The method according to claim 5, wherein the protein kinase inhibitor is co-administered to the subject with a tyrosine kinase inhibitor or an anti-microtubule agent.

7. The method according to claim 6, wherein the protein kinase inhibitor is administered to the subject prior to, in conjunction with, or subsequent to administration of the tyrosine kinase inhibitor or anti-microtubule agent.

8. The method according to claim 7, wherein the protein kinase inhibitor is co-administered to the subject with an anti-microtubule agent selected from docetaxel, paclitaxel, albumin-bound paclitaxel, and cabazitaxel.

9. The method according to claim 6, wherein the protein kinase inhibitor is co-administered to the subject with a tyrosine kinase inhibitor specific to the group of tyrosine kinase receptors selected from the group consisting of EGF receptor (EGFR), HER2/neu, c-SRC, hepatocyte growth factor receptor (HGFR), insulin-like growth factor 1 receptor, fibroblast growth factor receptor, platelet-derived growth factor receptor, and VEGF receptor; or gefitinib.

10. The method according to claim 1, wherein the disorder is cancer.

11. The method according to claim 10, wherein the cancer is selected from multiple myeloma, acute lymphocytic leukemia, acute and chronic myelogenous leukemia, chronic lymphocytic leukemia, acute lymphoblastic leukemia, promyelocytic leukemia, B-cell lymphoma, T-cell lymphoma, mantle cell lymphoma, hairy cell lymphoma, Burkiti's lymphoma, mast cell tumors, Hodgkin's disease, non-Hodgkin's disease, myelodysplasia syndrome, fibrosarcoma, rhabdomyosarcoma; astrocytoma, neuroblastoma, glioma, schwannomas, melanoma, seminoma, teratocarcinoma, osteosarcoma, xenodenna pigmentosum, keratoctanthoma, thyroid follicular cancer, Kaposi's sarcoma, melanoma, teratotna, rhabdomyosarcoma, metastatic and bone disorders, cancer of the bone, mouth/pharynx, esophagus, larynx, stomach, intestine, colon, rectum, lung, liver, pancreas, nerve, brain, head and neck, throat, ovary, uterus, prostate, testis, bladder, kidney, breast, gall bladder, cervix, thyroid, prostate, and skin, non-small cell lung cancer, small cell lung cancer, glioma, and glioblastoma multiforme.

12. The method according to claim 10, wherein the cancer is a metastatic cancer.

13. The method according to claim 12, wherein the cancer is a lung metastasis.

Description

DESCRIPTION OF THE DRAWINGS

(1) FIG. 1 represents an alignment of MENA protein isoforms with the functions of individual domains identified. The relative location of the 19 amino acid insertion characteristic of MENA.sup.INV is indicated by “\INV/” and the relative location of the 23 amino acid insertion of MENA.sup.11a is indicated by “\11a”.

(2) FIG. 2 presents Western blots of protein recovered from recombinant cell line MVD7-MENA.sup.INV probed with antibodies specific for presence of phosphorylated MENA at Scr125 (pSer125 MENA), phosphorylated P38 (pP38), phosphorylated HSP27 (pHSP27), and tubulin. Experimental samples were stimulated with TNF-alpha and treated with inhibitors, as indicated.

(3) FIG. 3 presents Western blots of protein recovered from recombinant cell line of MVD7-MENA.sup.INV probed with antibodies to phosphorylated Ser125 of MENA (pSer125 MENA) and tubulin. Experimental samples were stimulated with TNF-alpha and treated with inhibitors as indicated.

(4) FIG. 4 represents Western blots of protein recovered from recombinant cell line of MDA-MB-231 MENA.sup.INV probed with antibodies to phosphorylated Ser125 of MENA (pSer125 MENA), tubulin, and phosphorylated HSP27 (pHSP27). Experimental samples were stimulated with TNF-alpha and treated with inhibitors as indicated.

(5) FIG. 5 is a collection of photomicrographs of cell spreading assays of various recombinant MVD7 cell lines treated with various inhibitors. Panel (a) MENA-null GFP control, panel (b) GFP-MENA (Ser144A), panel (c) untreated MVD7-MENA.sup.INV, panel (d) MVD7-MENA.sup.INV treated with Pi3K kinase inhibitor LY294002 (PI3K-Ly02) 10 uM, panel (e) MVD7-MENA.sup.INV treated with p38 MAPK kinase inhibitor (LY2228820) 10 uM, panel (f) MVD7-MENA.sup.INV treated with MAPKAPK2/MK2 (PF-3644022) 10 uM, panel (g) MVD7-MENA.sup.INV treated with MEK1/MEK2 inhibitor (PD0325901) 1 uM, panel (h) MVD7-MENA.sup.INV treated with MAPKAPK2/MK2 kinase inhibitor KKKALHRQLGVAA (SEQ ID NO: 30) peptide (100 uM).

(6) FIG. 6 is a plot of the results of the cell spreading assays of FIG. 5, where MVD7-GFP corresponds to panel (a), MVD-Ser144A corresponds to panel (b), 0 corresponds to panel (c), Pi3K kinase inhibitor LY294002 (PI3K-Ly02) 10 uM corresponds to panel (d), p38 MAPK kinase inhibitor (P38-Ly820) 10 uM corresponds to panel (e), MEK1/MEK2 kinase inhibitor (ERK12-PD) 1 uM corresponds to panel (f), MAPKAPK2/MK2 kinase inhibitor Pfizer PF-3644022 10 uM corresponds to panel (g), and H&B-100 denotes KKKALHRQLGVAA (SEQ ID NO: 30) peptide inhibitor at 100 uM corresponds to panel (h). H&B-300 denotes KKKALHRQLGVAA (SEQ ID NO: 30) peptide inhibitor at 300 uM (not shown in FIG. 5).

(7) FIG. 7 is a collection of photomicrographs of fibronectin fibrillogenesis assays of the recombinant MVD7-MENA.sup.INV cell line (except as indicated in panels (a) and (b)) treated with various inhibitors and stained for DNA (DAPI) and for actin filaments (phalloidin) as well as fibronectin deposition. Panel (a) MVD7-GFP, panel (b) MVD7-MENA.sup.INV (Ser144A), panel (c) Pi3K kinase inhibitor (LY294002) 10 uM, panel (d) p38 MAPK kinase inhibitor (LY2228820) 10 uM, panel (e) MAPKAPK2/MK2 (PF-3644022) 10 uM, panel (f) MEK1/MEK2 inhibitor (PD0325901) 1 uM, and panels (g) MAPKAPK2/MK2 kinase inhibitor KKKALHRQLGVAA (SEQ ID NO: 30) peptide 100 and 300 uM, respectively.

(8) FIG. 8 is a plot of the results of the fibronectin fibrillogenesis assays (relative fibronectin deposition) of FIG. 7, where MVD7-GFP corresponds to panel (a), MVD7-Ser144A corresponds to panel (b), 0 represents fibronectin deposited by untreated MVD7-MENA.sup.INV cells, Pi3K kinase inhibitor LY294002 (PI3K-Ly02) 10 uM corresponds to panel (c), p38 kinase inhibitor LY2228820 (P38-Ly820) 10 uM corresponds to panel (d), MEK1/MEK2 inhibitor PD0325901 (ERK1/2-PD) 1 uM corresponds to panel (e), MAPKAPK2/MK2 kinase inhibitor (PF-3644022) 10 uM corresponds to panel (f), MAPKAPK2/MK2 kinase inhibitor KKKALHRQLGVAA (SEQ ID NO: 30) peptide (H&B-100) 100 uM corresponds to panel (g), and MAPKAPK2/MK2 kinase inhibitor KKKALHRQLGVAA (SEQ ID NO: 30) peptide (H&B-300) 300 uM corresponds to panel (h). Confidence levels are indicated by ** for P=0.0022, *** for P=0.0002, and **** for P<0.0001.

(9) FIG. 9 is a collection of photomicrographs of cell migration in wound assays of MDA-MB-231-MEAN.sup.INV cells treated with various inhibitors. Estimated percentage of wound closure is presented above each panel. Panel (a) is cells before treatment, panel (b) cells after 18 hours in media without inhibitor, panel (c) cells after 18 hours in media supplemented with Pi3K kinase inhibitor LY294002 (10 uM), panel (d) cells after 18 hours in media supplemented with p38 kinase inhibitor LY2228820 (10 uM), panel (e) cells after 18 hours in media supplemented with MAPKAPK2/MK2 kinase inhibitor PF-3644022 (10 uM), panel (f) cells after 18 hours in media supplemented with MEK1/MEK2 kinase inhibitor PD0325901 (1 uM), panels (g) cells after 18 hours in media supplemented with MAPKAPK2/MK2 kinase inhibitor KKKALHRQLGVAA (SEQ ID NO: 30) peptide (H&B-100) 100 uM and h) cells after 18 hours in media supplemented with MAPKAPK2/MK2 kinase inhibitor KKKALHRQLGVAA (SEQ ID NO: 30) peptide (H&B-100) 300 uM.

(10) FIG. 10 is a plot of the results of the cell invasion and chemotaxis Matrigel assay. MENA kinase inhibitors reversed the MENA-dependent invasion and chemotaxis phenotype in MDA-MD-231-MENA.sup.INV tumor cells following incubation with Pi3K kinase LY294002 10 uM, p38 kinase inhibitor LY2228820 (P38-Ly820) 10 uM, MAPKAPK2/MK2 kinase inhibitor (PF-3644022) 10 uM, MEK1 and MEK2 inhibitor PD0325901 (ERK1/2-PD) 1 uM, and KKKALHRQLGVAA (SEQ ID NO: 30) peptide inhibitor 100 and 300 uM. MDA-MB-231-ΔMENA CRISPR mena-null cell line did not show any significant cell invasion and chemotaxis phenotype with few cells observed to migrate towards EGF. Confidence levels are indicated by * for P<0.04.

(11) FIG. 11 is a plot of the result of cell migration and chemotaxis within the Boyden Chamber assay. MENA kinase inhibitors reversed the MENA-dependent migration and chemotaxis phenotype in MDA-MD-231MENA.sup.INV tumor cells following incubation with Pi3K kinase inhibitor LY294002 (PI3K-Ly02) 10 uM, p38 MAPK kinase inhibitor (LY2228820) 10 uM, MAPKAPK2/MK2 (PF-3644022) 10 uM, MEK1/MEK2 inhibitor PD0325901 (ERK1/2-PD) 1 uM and MAPKAPK2/MK2 kinase inhibitor KKKALHRQLGVAA (SEQ ID NO: 30) peptide 100 uM and 300 uM. Neither MDA-MB-231-ΔMENA CRISPR mena-null nor the non-phosphorylatable MENA-Ser144A cell lines exhibited the cell invasion and chemotaxis phenotype with few cells observed to migrate towards EGF. Confidence levels are indicated by ** for P<0.04 and *** for P<0.0004.

DETAILED DESCRIPTION OF THE INVENTION

(12) A method is provided for treating cancer in a patient with a solid tumor compromising reducing the presence or activity of the MENA and or MENA.sup.INV isoform of MENA in a subject and may further comprise increasing the presence or activity of the MENA.sup.11a isoform in a subject. The method involves inhibition of the phosphorylation or dephosphorylation of MENA and or the MENA.sup.INV protein isoform by administration of a drug that inhibits the transfer of phosphate groups to serine, threonine, and/or tyrosine residues in the MENA and or MENA.sup.INV isoform substrate by a MENA kinase. Similarly, the method involves activation of the phosphorylation or dephosphorylation of the MENA.sup.11a isoform substrate. The method may involve administration of MENA- and or MENA.sup.INV- and MENA.sup.11a-specific drugs as described herein to simultaneously reduce the presence or activity of MENA and or MENA.sup.INV and increase the presence or activity of MENA.sup.11a. As used herein, the term “MENA kinase inhibitor” refers to any composition which inhibits phosphorylation or dephosphorylation of a MENA isoform, including but not limited to MENA, MENA.sup.INV, and MENA.sup.11a.

(13) In an embodiment of the present invention the MENA kinase inhibitor is a small molecule, peptide, protein, antibody, monoclonal antibody, antibody fragment, RNA aptamer, ribozyme, or siRNA.

(14) In an embodiment the MENA kinase inhibitor is an ATP-competitive inhibitor. In another embodiment the MENA kinase inhibitor is a non-ATP competitive inhibitor.

(15) In an embodiment the MENA kinase inhibitor is a reversible inhibitor. In another embodiment the MENA kinase inhibitor is a non-reversible covalent inhibitor.

(16) In an embodiment the MENA kinase inhibitor is an inhibitor of the Ras-Raf-MEK-ERK and or PI3K-PTEN-ATk-mTOR pathways. Including, but not limited to Raf, p38 MAP, MEK, MAPK, PKD-1, PI3K, Akt, and mTOR inhibitors or a similar protein kinase inhibitors familiar to persons skilled in the art.

(17) In an embodiment the MENA kinase inhibitor is an inhibitor of the MAPK-activated protein kinase (MAPK kinase). As used herein the term “MAPK kinase” collectively refers to each and all of the several MAPK-activated protein kinases including, but not limited to MAPK-activated protein kinase 2 (MAPKAPK2 or MK2) inhibitor, MAPK-activated protein kinase 3 (MAPKAPK3 or MK3) inhibitor, MAPK-activated protein kinase 5 (MAPKAPK5 or MK5) inhibitor, or similar MAPK-activated protein kinase inhibitors familiar to persons skilled in the art. In a preferred embodiment the MENA kinase inhibitor specifically inhibits MAPKAPK2 (MK2).

(18) In an embodiment the MENA kinase inhibitor reduces or eliminates phosphorylation of one or more of Ser2, Ser5, Tyr16, Ser29, Thr30, Ser33, Tyr38, Thr41, Thr45, Tyr70, Thr74, Thr76, Tyr87, Ser93, Ser102, Ser113, Thr116, Thr119, Ser125, Ser136, Ser265, Ser266, Ser272, Thr275, Ser279, Ser284, Ser285, Ser287, Ser295, Thr300, Ser302, Ser327, Ser344, Thr345, Ser375, Ser381, Ser383, Thr390, Ser405, Thr410, Ser411, Ser414, Ser423, Ser425, Ser426, Thr428, Thr430, Ser442, Ser444, Ser449, Ser463, Thr464, Thr467, Ser477, Thr481, Ser482, Ser485, Ser486, Thr487, Ser488, Thr489, Thr493, Thr500, Thr502, Ser506, Ser508, Ser512, Ser516, Thr517, Ser520, Ser523, Tyr534, Ser550, Ser565, Ser567, or Thr569 amino acids in MENA (SEQ ID NO.: 1). In a preferred embodiment the MENA kinase inhibitor eliminates phosphorylation of Ser125 of the MENA protein.

(19) In another embodiment the MENA kinase inhibitor reduces or eliminates dephosphorylation of one or more of phosphorylated Ser2, Ser5, Tyr16, Ser29, Thr30, Ser33, Tyr38, Thr41, Thr45, Tyr70, Thr74, Thr76, Tyr87, Ser93, Ser102, Ser113, Thr116, Thr119, Ser125, Ser136, Ser265, Ser266, Ser272, Thr275, Ser279, Ser284, Ser285, Ser287, Ser295, Thr300, Ser302, Ser327, Ser344, Thr345, Ser375, Ser381, Ser383, Thr390, Ser405, Thr410, Ser411, Ser414, Ser423, Ser425, Ser426, Thr428, Thr430, Ser442, Ser444, Ser449, Ser463, Thr464, Thr467, Ser477, Thr481, Ser482, Ser485, Ser486, Thr487, Ser488, Thr489, Thr493, Thr500, Thr502, Ser506, Ser508, Ser512, Ser516, Thr517, Ser520, Ser523, Tyr534, Ser550, Ser565, Ser567, or Thr569 amino acids in MENA (SEQ ID NO.: 1). In a preferred embodiment the MENA kinase inhibitor eliminates dephosphorylation of phosphorylated Ser125 of the MENA protein.

(20) In an embodiment the MENA kinase inhibitor reduces or eliminates phosphorylation of one or more of Ser3, Thr6, Thr8, Ser11, Thr12 of the MENA INV exon (SEQ ID NO.:2), or amino acids proximally flanking the MENA.sup.INV exon sequence at positions 117-135 of the MENA.sup.INV protein (SEQ ID NO.: 3). In a preferred embodiment the MENA kinase inhibitor reduces or eliminates phosphorylation of Ser144 of the MENA.sup.INV protein isoform.

(21) In an embodiment the MENA kinase inhibitor reduces or eliminates phosphorylation of one or more of Ser2, Ser5, Tyr16, Ser29, Thr30, Ser33, Tyr38, Thr41, Thr45, Tyr70, Thr74, Thr76, Tyr87, Ser93, Ser102, Ser113, Thr116, Ser119, Thr122, Thr124, Ser127, Thr128, Thr138, Ser144, Ser155, Ser284, Ser285, Ser306, Thr294, Ser303, Ser304, Ser306, Ser134, Thr319, Ser321, Ser346Ser363, Thr364, Ser394, Ser400, Ser402, Ser409, Ser424, Thr429, Ser430, Ser433, Ser442, Ser444, Ser445, Thr447, Thr449, Ser461, Ser468, Ser482, Thr483, Thr486, Ser496, Thr500, Ser501, Ser504, Ser505, Thr506, Ser507, Thr508, Thr512, Thr519, Thr521, Ser525, Ser527, Ser531, Ser535, Thr536, Ser539, Ser542, Thr548, Tyr553, Thr569, ser584, Ser586, or Thr588 amino acids in MEAN.sup.INV (SEQ ID NO.: 3). In a preferred embodiment the MENA kinase inhibitor eliminates phosphorylation of Ser144 of the MENA.sup.INV protein isoform.

(22) In an embodiment the MENA kinase inhibitor reduces or eliminates dephosphorylation of one or more of phosphorylated Ser3, Thr6, Thr8, Ser11, Thr12 of the MENA INV exon (SEQ ID NO.: 2), or phosphorylated amino acids proximally flanking the MENA.sup.INV exon sequence at positions 117-135 of the MENA.sup.INV protein (SEQ ID NO.: 3). In a preferred embodiment the MENA kinase inhibitor reduces or eliminates dephosphorylation of phosphorylated Ser144 of the MENA.sup.INV protein isoform.

(23) In an embodiment the MENA kinase inhibitor reduces or eliminates phosphorylation of one or more of phosphorylated Ser2, Ser5, Tyr16, Ser29, Thr30, Ser33, Tyr38, Thr41, Thr45, Tyr70, Thr74, Thr76, Tyr87, Ser93, Ser102, Ser113, Thr116, Ser119, Thr122, Thr124, Ser127, Thr128, Thr138, Ser144, Ser155, Ser284, Ser285, Ser306, Thr294, Ser303, Ser304, Ser306, Ser134, Thr319, Ser321, Ser346Ser363, Thr364, Ser394, Ser400, Ser402, Ser409, Ser424, Thr429, Ser430, Ser433, Ser442, Ser444, Ser445, Thr447, Thr449, Ser461, Ser468, Scr482, Thr483, Thr486, Ser496, Thr500, Ser501, Ser504, Ser505, Thr506, Ser507, Thr508, Thr512, Thr519, Thr521, Ser525, Ser527, Ser531, Ser535, Thr536, Ser539, Ser542, Thr548, Tyr553, Thr569, ser584, Ser586, or Thr588 amino acids in MENA.sup.INV (SEQ ID NO.: 3). In a preferred embodiment the MENA kinase inhibitor eliminates dephosphorylation of phosphorylated Ser144 of the MENA.sup.INV protein isoform.

(24) In an embodiment the MENA kinase inhibitor reduces or eliminates phosphorylation of one or more of Ser3, Ser15, Tyr16, Ser18 of the MENA.sup.11a exon (SEQ ID NO.: 4), amino acids proximally flanking the MENA.sup.11a exon sequence at positions 514-534 of the MENA.sup.11a protein (SEQ ID NO.: 5), or Ser125 of SEQ ID NO.:5.

(25) In an embodiment the MENA kinase inhibitor reduces or eliminates phosphorylation of one or more of Ser2, Ser5, Tyr16, Ser29, Thr30, Ser33, Tyr38, Thr41, Thr45, Tyr70, Thr74, Thr76, Tyr87, Ser93, Ser102, Ser113, Thr116, Thr119, Ser125, Ser136, Ser265, Ser266, Ser272, Thr275, Ser279, Ser284, Ser285, Ser287, Ser295, Thr300, Ser302, Ser327, Ser344, Thr345, Ser375, Ser381, Ser383, Thr390, Ser405, Thr410, Ser411, Ser414, Ser423, Ser425, Ser426, Thr428, Thr430, Ser442, Ser444, Ser463, Thr464, Ser477, Thr481, Ser482, Ser485, Ser486, Thr487, Ser488, Thr489, Thr493, Thr500, Thr502, Ser506, Ser508, Ser512, Ser516, Ser528, Tyr529, Ser531, Ser537, Thr538, Ser541, Ser544, Thr550, Tyr555, Thr571, Ser586, Ser588, or Thr590 amino acids in MENA.sup.11a (SEQ ID NO.: 5). In a preferred embodiment the MENA kinase inhibitor eliminates phosphorylation of Ser125 of the MENA.sup.11a protein isoform.

(26) In an embodiment the MENA kinase inhibitor reduces or eliminates dephosphorylation of one or more of phosphorylated Ser3, Ser15, Tyr16, Ser18 of the MENA.sup.11a exon (SEQ ID NO.: 4), phosphorylated amino acids proximally flanking the MENA.sup.11a exon sequence at positions 514-534 of SEQ ID NO.: 5, or Ser125 of SEQ ID NO.: 5.

(27) In an embodiment the MENA kinase inhibitor reduces or eliminates dephosphorylation of one or more of phosphorylated Ser2, Ser5, Tyr16, Ser29, Thr30, Ser33, Tyr38, Thr41, Thr45, Tyr70, Thr74, Thr76, Tyr87, Ser93, Ser102, Ser113, Thr116, Thr119, Ser125, Ser136, Ser265, Ser266, Ser272, Thr275, Ser279, Ser284, Ser285, Ser287, Ser295, Thr300, Ser302, Ser327, Ser344, Thr345, Ser375, Ser381, Ser383, Thr390, Ser405, Thr410, Ser411, Ser414, Ser423, Ser425, Ser426, Thr428, Thr430, Ser442, Ser444, Ser463, Thr464, Ser477, Thr481, Ser482, Ser485, Ser486, Thr487, Ser488, Thr489, Thr493, Thr500, Thr502, Ser506, Ser508, Ser512, Ser516, Ser528, Tyr529, Ser531, Ser537, Thr538, Ser541, Ser544, Thr550, Tyr555, Thr571, Ser586, Ser588, or Thr590 amino acids in MENA.sup.11a (SEQ ID NO.: 5). In a preferred embodiment the MENA kinase inhibitor eliminates dephosphorylation of phosphorylated Ser125 of the MENA.sup.11a protein.

(28) In an embodiment the MENA kinase inhibitor is a small molecule inhibitor that specifically inhibits phosphorylation or dephosphorylation of MENA or a MENA isoform kinase.

(29) In some embodiments the small molecule MENA kinase inhibitor is based on scaffolds, such as aminocyoanopyridine, pyrazolopyrimidines, pyrrolopyridine, carboline, pyrrolopyrimidone, and CMPD 1. In preferred embodiments the small molecule inhibitor specifically inhibits phosphorylation or dephosphorylation of MENA and or a MENA isoform by MENA kinase.

(30) In an embodiment the MENA kinase inhibitor is a peptide inhibitor that specifically inhibits phosphorylation or dephosphorylation of MENA and or a MENA isoform by MENA kinase.

(31) In an embodiment of the present invention the MENA kinase inhibitor comprises at least one of the peptides LPRQNGQLP (SEQ ID NO: 6), LARQNGQLP (SEQ ID NO: 7), KALPRQNGQLP (SEQ ID NO: 8), and KALARQNGQLP (SEQ ID NO: 9).

(32) In an embodiment the MENA kinase inhibitor is linked to a cell-penetrating peptide carrier sequence to facilitate uptake and delivery including, but not limited to HIV TAT peptide sequence. In certain embodiments the cell-penetrating carrier sequence based on the HIV TAT peptide sequence comprises at least one of the peptides YARAAARQARA (SEQ ID NO: 10), and YGRKKRRQRRR (SEQ ID NO: 11). Other cell-penetrating carrier forms are expressly contemplated. For example, KAFAKLAARLYR (SEQ ID NO: 12) and FAKLAARLYR (SEQ IS NO: 13) based on the antithrombin III heparin-binding domain.

(33) In certain embodiments the MENA kinase inhibitor comprises at least one of the peptides YARAAARQARALPRQNGQLP (SEQ ID NO: 14), YARAAARQARALARQNGQLP (SEQ ID NO: 15), YARAAARQARAKALPRQNGQLP (SEQ ID NO: 16), YARAAARQARAKALARQNGQLP (SEQ ID NO: 17), YGRKKRRQRRRLPRQNGQLP (SEQ ID NO: 18), YGRKKRRQRRRLARQNGQLP (SEQ ID NO: 19), YGRKKRRQRRRKALPRQNGQLP (SEQ ID NO: 20), YGRKKRRQRRRKALARQNGQLP (SEQ ID NO: 21), KAFAKLAARLYRKALPRQNGQLP (SEQ ID NO: 22), KAFAKLAARLYRKALARQNGQLP (SEQ ID NO: 23), KAFAKLAARLYRKAKALPRQNGQLP (SEQ ID NO: 24), KAFAKLAARLYRKAKALARQNGQLP (SEQ ID NO: 25) FAKLAARLYRKALPRQNGQLP (SEQ ID NO: 26), FAKLAARLYRKALARQNGQLP (SEQ ID NO: 27), FAKLAARLYRKAKALPRQNGQLP (SEQ ID NO: 28), and FAKLAARLYRKAKALARQNGQLP (SEQ ID NO: 29).

(34) Peptides were synthesized using standard solid phase peptide chemistry with FMOC protected amino acids on resin. Amino acid activation and coupling was carried out with HBTU/HOBt and DIEA. FMOC groups are removed using 20% piperidine in DMF. The resin-bound sequence was then cleaved and deprotected with 80-90% TFA containing a variety of scavengers which can include water, thioanisole, ethylmethylsulfide, and ethanedithiol, and/or triisopropylsilane. Peptides were precipitated into ether and then isolated by centrifugation. The dried peptide pellets reconstituted in a water and acetonitrile mixture and lyophilized prior to purification by reverse phase HPLC on a C18 column, which was eluted with acetonitrile-water buffers containing 0.1% TFA. Each peptide is analyzed and pure fractions are pooled and lyophilized. Analytical HPLC data was obtained on a 5 micron C18 analytical column and eluted with water-acetonitrile buffers containing 0.1% TFA. Molecular weight was confirmed by MALDI-TOF analysis.

(35) In an embodiment a medicament comprising a MENA kinase inhibitor is prophylactically administered to a subject in need thereof to prevent development of metastatic cancer or progression of fibrotic disease. A medicament comprising a MENA kinase inhibitor may also be administered therapeutically to reduce metastasis of an existing metastatic cancer.

(36) In other embodiments a MENA kinase inhibitor may be administered prior to, in conjunction with, or subsequent to, administration of TKI therapeutics specific to receptor tyrosine kinases that target EGF receptor (EGFR), HER2/neu, c-SRC, hepatocyte growth factor receptor (HGFR), fibroblast growth factor receptor, insulin-like growth factor receptor (IGFR), platelet-derived growth factor receptor, vascular endothelial growth factor receptors, and other cancer associated targets known to those skilled in the art, to improve or prolong the efficacy of the TKI therapeutic. In addition, the MENA kinase inhibitor may be administered in conjunction with other mitogen activated protein kinase inhibitors.

(37) In an embodiment a MENA kinase inhibitor is administered to treat a MENA-mediated disease or disorder, wherein the MENA-mediated disease or disorder is an autoimmune disorder, chronic or acute inflammatory disorder, auto-inflammatory disorder, a fibriotic disorder, a metabolic disorder, a neoplasia, or a cardiovascular or cerebrovascular disorder.

(38) In further embodiment the fibriotic disorder is selected from the group consisting of systemic sclerosis/scleroderma, lupus nephritis, connective tissue disease, wound healing, surgical scarring, spinal cord injury, CNS scarring, acute lung injury, pulmonary fibrosis, idiopathic pulmonary fibrosis, cystic fibrosis, chronic obstructive pulmonary disease, adult respiratory distress syndrome, acute lung injury, drug-induced lung injury, glomerulonephritis, chronic kidney disease, diabetic nephropathy, hypertension-induced nephropathy, alimentary track or gastrointestinal fibrosis, renal fibrosis, hepatic or biliary fibrosis, liver fibrosis, nonalcoholic steatohepatitis, hepatitis C, hepatocellular carcinoma, cirrhosis, primary biliary cirrhosis, cirrhosis due to fatty liver disease cirrhosis due to alcoholic fatty liver disease, cirrhosis due to nonalcoholic steatosis/non-alcoholic fatty liver disease, radiation-induced fibrosis head and neck fibrosis, gastrointestinal fibrosis, pulmonary fibrosis, primary sclerosing cholangitis, restenosis, cardiac fibrosis, endomyocardial fibrosis, atrial fibrosis, ophthalmic scarring, fibrosclerosis, fibrotic cancers, fibroids, fibroma, fibroadenomas, fibrosarcomas, transplant mteriopathy, keloid, mediastinal fibrosis, myelofibrosis, retroperitoneal fibrosis, progressive massive fibrosis, and nephrogenic systemic fibrosis.

(39) In further embodiment the neoplasia is selected from the group consisting of angiogenesis disorders, multiple myeloma, leukemias, acute lymphocytic leukemia, acute and chronic myelogenous leukemia, chronic lymphocytic leukemia, acute lymphoblastic leukemia, promyelocytic leukemia, lymphomas, B-cell lymphoma, T-cell lymphoma, mantle cell lymphoma, hairy cell lymphoma, Burkitt's lymphoma, mast cell tumors, Hodgkin's disease, non-Hodgkin's disease, myelodysplasia syndrome, fibrosarcoma, rhabdomyosarcoma; astrocytoma, neuroblastoma, glioma, schwannomas, melanoma, seminoma, teratocarcinoma, osteosarcoma, xenodenna pigmentosum, keratoctanthoma, thyroid follicular cancer, Kaposi's sarcoma, melanoma, teratoma, rhabdomyosarcoma, metastatic and bone disorders, cancer of the bone, mouth/pharynx, esophagus, larynx, stomach, intestine, colon, rectum, lung, liver, pancreas, nerve, brain, head and neck, throat, ovary, uterus, prostate, testis, bladder, kidney, breast, gall bladder, cervix, thyroid, prostate, and skin, non-small cell lung cancer, small cell lung cancer, glioma, and glioblastoma multiforme.

(40) In further embodiment the cardiovascular or cerebrovascular disorder is selected from the group consisting of atherosclerosis, restenosis of an atherosclerotic coronary artery, acute coronary syndrome, myocardial infarction, cardiac-allograft vasculopathy, stroke, central nervous system disorders with an inflammatory or apoptotic component, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinal cord injury, neuronal ischemia and peripheral neuropathy.

(41) In other embodiments a MENA kinase inhibitor may be administered prior to, in conjunction with, or subsequent to, administration of anti-microtubules drugs including but not limited to taxel, docetaxel, paclitaxel, albumin-bound paclitaxel or any other anti-microtubule associated drugs known to those skilled in the art.

EXAMPLES

(42) The following examples illustrate the scope of the invention. Specific elements of the examples are for descriptive purposes only and are not intended to limit the scope of the invention. Those skilled in the art could develop equivalent methods and utilize comparable materials that are within the scope of the invention.

Example 1

(43) MENA Isoform Phosphorylation and Related Reagents and Assays

(44) MENA Isoforms are Differentially Phosphorylated.

(45) Analysis of MENA.sup.INV in tumor cells found in TMEMs (Tumor Micro Environment of Metastasis) indicates that the protein is actively phosphorylated. Differences in phosphorylation between MENA.sup.INV and MENA suggest that the phosphorylated amino acids are associated with the 19 amino acids characteristic of MENA.sup.INV which are absent in MENA. Similar observations from analysis of non-metastatic tumor cells expressing MENA.sup.11a indicate that the 21 amino acids characteristic of that isoform of MENA may also represent targets for phosphorylation. Importantly, the effect on phosphorylation of each of the MENA isoform insertions (relative to MENA) may not be due only to phosphorylation of amino acids within the MENA.sup.INV and MENA.sup.11a sequences, but may affect phosphorylation of MENA amino acids in close proximity (spatially or in adjacent sequences) to the and MENA.sup.11a sequences.

(46) To determine which of the potential amino acid residues associated with, or in proximity to, the MENA.sup.INV and MENA.sup.11a insertions may be phosphorylated, a series of recombinant MENA.sup.INV and MENA.sup.11a constructs was produced to express modified MENA isoform variants with the candidate residues changed to amino acids that cannot be phosphorylated. In one example, serine was substituted with alanine, which has a similar R-group but lacks the hydroxyl group necessary for phosphoryl transfer. In other examples, tyrosine may be substituted with phenylalanine. Threonine may be substituted with either alanine or asparagine to block phosphorylation. Materials and methods for generating such mutants are well known to those of skill in the art (see for example, the Gene Art™ Site Directed Mutagenesis System (Life Technologies Corp., Grand Island, N.Y.), the Q5® Sire-Directed Mutagenesis Kit (New England Biolabs Inc., Beverly, Mass.), and the Quick-changes Site-Directed Mutagenesis Kit (Strata gene, La Jolla, Calif.)), The ability of tumor cell extracts to phosphorylate the modified MENA.sup.INV and MENA.sup.11a variant proteins was examined. Variants with significantly reduced levels of phosphorylation represent the amino acid target(s) for phosphorylation by tumor cell kinase(s). Such tumor cell kinases may be considered MENA isoform kinases.

(47) Anti-phospho-MENA antibodies specific for the Ser125/Ser144 phosphorylation site in MENA/MENA.sup.INV were produced in animals injected with peptide containing mouse MENA residues 117-133 phosphorylated at Ser125 and conjugated to KLH (Covance Research Products, Denver, Pa.). Purification of pSer125MENA antibody was performed according to the protocol of Archuleta, et al. (Archuleta, Stutzke, Nixon, & Browning, Optimized protocol to make phospho-specific antibodies that work. Methods Mol. Biol. 717:69-88, 2011). Peptides used for purification (phosphorylated peptide: Ac-CKKGPTLPRQN(pS)QLPAQVQN (SEQ ID NO: 32) and dephosphorylated: CKKGPTLPRQNSQLPAQVAN (SEQ ID NO:32)) were prepared by Covance Research Products (BioLegend, San Diego, Calif.) and ThermoScientific, Grand Island, N.Y., respectively. Peptides were coupled to SulfoLink Coupling Resin Column (ThermoScientific) according to manufacturer's instructions. Sera were sequentially passed over column containing dephosphorylated peptide, and then over the column containing phosphorylated peptide. Antibodies bound to second column were eluted using IgG Elution buffer (ThermoScientific).

(48) Phosphorylation of MENA and or MENA isoforms is inhibited by MENA kinase inhibitors from the Ras-Raf-MEK-MAPK/ERK and PI3K-AKT/mTOR pathways. The ATP-competitive MAPKAPK2/MK2 inhibitor PF-3644022 ((10R)-9,10,11,12-tetrahydro-10-methyl-3-(6-methyl-3-pyridinyl)-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-f]quinolin-8-one hydrate) (TOCRIS, Bristol, UK), the non ATP-competitive MAPKAPK2/MK2 Hayess and Benndorf HSP25 peptide kinase inhibitor (KKKALNRQLGVAA (SEQ ID NO.: 30)) (Abcam, Cambridge, UK), p38 MAPK kinase inhibitor LY2228820 (5-[2-tert-butyl-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)imidazo[4,5-b]pyridin-2-amine; methanesulfonic acid) (Selleckchem, Houston Tex.), MEK1/MEK2 non ATP-competitive inhibitor PD0325901 (N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-benzamide) (Selleckchem, Houston Tex.), and Pi3K inhibitor LY294002 (2-morpholin-4-yl-8-phenylchromen-4-one) (Selleckchem, Houston Tex.) were each evaluated in vitro for the ability to block MENA kinase-dependent phosphorylation of Ser125 and Ser144 of MENA and MENA.sup.INV respectively, in mutant MVD7 and MDA-MB-231 cell lines. Phosphorylation was measured by quantitative immunoblot assays using MENA antibodies specific for the phosphorylation of MENA/MENA.sup.INV at Ser125/Ser144 Cells were stimulated and the MENA kinase was activated through treatment with 10 ng/ml TNF-alpha. Under these conditions MENA undergoes MENA kinase-dependent phosphorylation at Ser125 and MENA.sup.INV undergoes MENA kinase-dependent phosphorylation at Ser144. Commercially available phospho-specific HSP27 antibody (CellSignalling, Danvers, Mass.) was used to monitor MENA kinase-dependent phosphorylation of HSP27 as an internal control.

(49) As shown in FIG. 2, the pSer125-specific antibody clearly differentiates between unphosphorylated MENA/MENA.sup.INV and phosphorylated MENA/MENA.sup.INV, Comparison of the extent of antibody binding in the lane labeled “Medium” and the lane labeled “Sodium Arsenate” shows in the recombinant mouse embryonic fibroblast MVD7 cell line engineered to express MENA.sup.INV (MVD7-MENA.sup.INV), the pSer125 MENA antibody produces very little signal in protein from cells that have minimal phosphorylation of MENA.sup.INV (“Medium”). The same cells when treated with sodium arsenate (osmotic stress inducer) to chemically modify the phosphorylatable sites of MENA.sup.INV, produce a distinct signal when probed with the pSer125 MENA antibody. The Ser144 position of MENA.sup.INV is equivalent to Ser125 of MENA, with the difference in position solely due to the presence of the INV exon in MENA.sup.INV. The pSer125 MENA antibody binds the Ser144 position of MENA.sup.INV as well as it binds the Ser125 position of MENA. Furthermore, comparison of the unstimulated and untreated (Medium) with the stimulated untreated (0) sample in FIG. 2 indicates stimulation of cells with TNF-alpha also elevates phosphorylation of MENA.sup.INV. Shown in FIG. 2, treatment of stimulated cells with the p38 MAPK kinase inhibitor LY2228820 (at 1 uM, lane “P38-Ly820 1 uM”)), MAPKAPK2/MK2 kinase inhibitor PF-3644022 (at 10 uM, lane “Pfizer 10 uM”)), and MEK1/MEK2 inhibitor PD0325901 (at 1 uM, lane “ERK1/2-PD-1 uM”)) significantly reduce the level of phosphorylated MENA.sup.INV.

(50) FIG. 3 confirms this observation and extends the panel of inhibitors of FIG. 2 to include Pi3K kinase inhibitor LY294002 (at 1 and 10 uM, lanes “P38-Ly820 1 uM” and “P38-Ly820 1 uM”, respectively) and the MAPKAPK2/MK2 kinase inhibitor KKKALHRQLGVAA (SEQ ID NO: 30) peptide at 50, 100, and 300 uM, lanes labeled “H&B” at the indicated inhibitor concentration. As shown in FIG. 4, human breast cancer MDA-MB-231 cells engineered to express MENA.sup.INV (MDA-MB-123-MENA.sup.INV) clearly express elevated levels of phosphorylated Ser144, which can be detected using the antibody described above and as shown in lanes containing protein from cells unstimulated and untreated (0). Lanes labeled “P13K-Ly02-10 uM” are protein from stimulated cells treated with 10 uM of p38 MAPK kinase inhibitor LY2228820. Lanes labeled “P13K-Ly02-10 uM” and “P13K-Ly02-1 uM” contain protein from stimulated cells treated with 10 uM and 1 uM of Pi3K kinase inhibitor LY294002, respectively. Lanes labeled “Pfizer 10 uM” contain protein from stimulated cells treated with 10 uM of MAPKAPK2/MK2 kinase inhibitor PF-3644022. Lanes labeled ERK1/2-PD-1 uM contain protein from stimulated cells treated with 1 uM of MEK1/MEK2 inhibitor PD0325901, and lanes labeled “H&B” contain protein from stimulated cells treated with MAPKAPK2/MK2 kinase inhibitor KKKALHRQLGVAA (SEQ ID NO: 30) peptide at the indicated concentrations.

(51) MENA kinase inhibitors limit cell spreading of MENA isoform recombinant cell lines. The ability of the various MENA kinase inhibitors described above to limit cell spreading of a MENA.sup.INV recombinant MVD7 (MVD7-MENA.sup.INV) cell line was evaluated using a cell spreading assay. The assay involved pretreatment of the cell line with or without MENA kinase inhibitor at the concentrations indicated in FIG. 5 for 1 hour. Following pretreatment, the MVD7-MENA.sup.INV cells were allowed to attach and spread on fibronectin for 20 minutes. After 20 minutes the cells were fixed, permeabilized and stained with Phalloidin to visualize actin filaments. Images were acquired using imageJ software and analyzed (anova, n=5). Treatment groups were compared to control MVD7-GFP cells and plotted as Mean with S.E.M. as shown in FIG. 6.

(52) The MVD7-MENA.sup.INV cell shown in FIG. 5 panel (c) exhibited the MENA dependent spreading and adhesion phenotype which was not observed for the MVD7-GFP MENA-null control nor for the non-phosphorylatable MVD7-MENA.sup.INV (Ser144A) cells (FIG. 5, panels (a) and (b), respectively). Statistically significant reductions in the MENA-dependent spreading and adhesion phenotype were observed following incubation with the MENA kinase inhibitors at the indicated concentrations (FIG. 6). Statistically significant decreases in the MENA-dependent spreading and adhesion phenotype occurred with all MENA kinase inhibitors (FIG. 6). There were no statistically significant differences in spreading and adhesion between the MENA-null and MENA Ser125A non phosphorylatable mutant negative controls (FIG. 6.).

(53) MENA kinase inhibitors reversed MENA-dependent fibrillogenesis. The ability of the various MENA kinase inhibitors described above to reverse MENA-dependent fibrillogenesis was evaluated in fibronectin fibrillogenesis assays using the MVD7-MENA.sup.INV cell line. Cells were pretreated with MENA kinase inhibitor for 1 hour at the concentrations indicated in FIG. 8 and cultured in medium containing fibronectin-depleted serum supplemented with labeled fibronectin. After 4 hours, fibronectin fibril formation was evaluated by quantitative immunostaining using imageJ software to measure abundance and distribution of fibrillar fibronectin (anova, n=3). The results are plotted relative to control MVD7-GFP cells in FIG. 8.

(54) Untreated MVD7-MENA.sup.INVv cells assemble a significant amount of fibronectin in fibrils (FIG. 7, panel (a). However, MVD7-GFP cells and the non-phosphorylatable mutant MENA.sup.INV (Ser144A) (FIG. 8 and FIG. 7 panel (b), respectively) fail to assemble a significant amount of fibronectin. Dose-dependent reductions in the MENA-dependent fibronectin fibrillogenesis phenotype were observed with increasing concentrations of the MAPKAPK2/MK2 kinase inhibitor KKKALHRQLGVAA (SEQ ID NO: 30) peptide at the concentrations of 100 and 300 uM (FIG. 7, panel (g) and FIG. 8). Statistically significant decreases in the MENA-dependent fibronectin fibrillogenesis phenotype was observed for all the Mena kinase inhibitors tested. Pi3K kinase inhibitor LY294002, MEK1/MEK2 kinase inhibitor PD0325901, and MAPKAPK2/MK2 kinase inhibitor KKKALHRQLGVAA (SEQ ID NO: 30) significantly reduced the MENA-dependent fibronectin fibrillogenesis phenotype compared to the MENA-null control (FIG. 8). There were no statistically significant differences in fibronectin deposition between the MENA-null negative control and MENA Ser144A non phosphorylatable mutant.

(55) MENA kinase inhibitors block MENA-dependent cell migration in a wound-healing assay. The ability of the various MENA kinase inhibitors described above to block MENA-dependent cell migration of MDA-MB-231-MENA.sup.INV cells was assayed using the CySelect™ wound healing assay kit (Cell Biolabs, Inc., San Diego, Calif.). Following the manufacturer's protocol, cells were cultured in fibronectin coated wells until a monolayer formed around the wound insert. The insert was then removed and cells were cultured in the presence of inhibitor at the indicated concentrations in FIG. 9 in fully supplemented medium. After 18 hours the cells were fixed, stained, and evaluated for their capacity to close the wound generated by the insert by fluorescence microscopy.

(56) As shown in FIG. 9, MDA-MB-231-MENA.sup.INV cells exhibit the MENA-dependent invasion phenotype in fully supplemented medium (panel (b)). Addition of MENA kinase inhibitors to cells grown in fully supplemented medium reduce the capability of the breast cancer cell line to migrate in the wound healing assay (panels (c)-(h)). Panel (a) represents the wound size at the start of treatment. Cells that were cultured overnight in fully supplemented medium without drug (panel (b)) were able to close 50% of the wound. Addition of the Pi3K kinase inhibitor LY294002 (10 uM) resulted in wound closure of only 15% (panel (c)), p38 MARK kinase inhibitor LY2228820 (10 uM) produced closure of only 20% (panel (d)), MAPKAPK2/MK2 kinase inhibitor PF-3644022 (10 uM) reduced wound closure to 10% (panel (e)), MEK1/MEK2 kinase inhibitor PD0325901 (1 uM) reduced wound closure to 15% (panel (f)), and the MAPKAPK2/MK2 kinase inhibitor KKKALHRQLGVAA (SEQ ID NO: 30) reduced wound closure to 15% of the wound when used at 300 uM (panel (h)). MENA kinase inhibitors inhibit MENA-dependent cell invasion and chemotaxis. The ability of the various MENA kinase inhibitors described above to inhibit MDA-MB-123-MENA.sup.INV tumor cell invasion was tested using the BioCoat™ Matrigel® invasion chamber assay (Corning, Tewksbury, Mass.). Following the manufacturer's protocol, MDA-MB-123-MENA.sup.INV cells were pretreated for 1 hour with inhibitor at the concentrations indicated in FIG. 10, then seeded above the layer of matrigel matrix membrane inserts. Inserts were transferred to wells containing basal media (negative control) and the chemoattractant EGF with or without each of the MENA kinase inhibitors. After 18 hours cells that invaded the lower cell surface of the membrane were fixed, stained and evaluated by quantitative immunostaining using imageJ software. Data were analyzed using anova, n=3 and reported relative to the negative control EGF stimulated cells in the absence of MENA kinase inhibitors (0) and plotted as the mean and standard error of the mean in FIG. 10.

(57) MDA-MB-231-MENA.sup.INV cells exhibit the invasive and chemotactic phenotype in basal medium containing EGF, compared to the MDA-MB-231-ΔMENA cell line, in which all endogenous MENA expression is deleted from the cell line using CRISPR-based techniques (FIG. 10). The addition of MENA kinase inhibitors significantly reduce the relative number of MDA-MB-231-MENA.sup.INV cells that invade through Matrigel insert membranes towards the EGF chemoattractant. The effect of incubation with the Pi3K kinase inhibitor LY294002 (10 uM) (P<0.028), p38 MARK kinase inhibitor LY2228820 (10 uM) (P<0.019), MAPKAPK2/MK2 kinase inhibitor PF-3644022 (10 uM) (P<0.040), MEK1/MEK2 PD0325901 (1 uM) (P<0.040) and MAPKAPK2/MK2 kinase inhibitor KKKALHRQLGVAA (SEQ ID NO: 30) (100 and 300 uM) (P<0.019 and P<0.020, respectively) are shown in FIG. 10. MENA kinase inhibitors significantly reversed the MENA-dependent invasion phenotype in MDA-MB-231-MENA.sup.INV cells to levels similar to the negative control, MDA-MB-23 I-MENA.sup.INV treated with basal medium only (Basal Medium).

(58) MENA kinase inhibitors reverse MENA-dependent cell migration and chemotaxis in the Boyden Chamber Assay. MDA-MB-123-MENA.sup.INV tumor cells were pretreated with the MENA kinase inhibitors described above for 1 hour and loaded into the fibronectin coated 8 um pore polycarbonate membrane insert of the Boyden Chamber (Cell Biolabs, Inc.). The fibronectin coated upper chamber were then transferred to wells containing basal media (negative controls) and wells containing basal media, EGF, and MENA kinase inhibitors at the concentrations indicated in FIG. 11. All treatment conditions except the basal negative control used EGF as the chemoattractant. After 18 hours, cells that migrated through the pores toward the chemotattractant were evaluated by quantitative immunostaining using imageJ software as described above. Data were analyzed using anova (n=2) and reported relative to the EGF stimulated cells absent any inhibitor positive control (0) as mean with error of the mean in FIG. 11.

(59) MDA-MB-231-MENA.sup.INV cells demonstrate the migration and chemotaxis MENA dependent-phenotype in basal medium containing EGF. This phenotype was not observed in MDA-MB-231-ΔMENA and non-phosphorylatable MENA-Ser144A cell lines using similar experimental conditions (FIG. 11). The addition of MENA kinase inhibitors significantly reduced the relative number of MDA-MB-231-MENA.sup.INV cells that migrated through the fibronectin coated insert membrane towards the EGF chemoattractant. Incubation with Pi3K kinase inhibitor LY294002 (10 uM) (P<0.028), p38 MARK kinase inhibitor LY2228820 (10 uM) (P<0.0018), MAPKAPK2/MK2 kinase inhibitor PF-3644022 (10 uM) (P<0.0018), MEK1/MEK2 kinase inhibitor PD0325901 (1 uM) (P<0.0031) and MAPKAPK2/MK2 kinase inhibitor KKKALHRQLGVAA (SEQ ID NO: 30) 100 and 300 uM (P<0.0004), (P<0.0004) significantly reverse the MENA-dependent invasion phenotype in MDA-MB-231-MENA.sup.INV cells to levels similar to the negative control, MDA-MB-231-MENA.sup.INV treated with basal medium only.

Example 2

(60) Identifying Small Molecule MENA Isoform Kinase Inhibitors

(61) Small molecule MENA isoform kinase inhibitors are identified by use of the same (or similar) panel of in vitro assays as described in Example 1. To identify small molecule inhibitors of MENA kinases, single molecules, or pools of molecules, from commercial combinatorial chemical libraries of compounds based on known protein kinase inhibitor structures (scaffolds), such as aminocyoanopyridine, pyrazolopyrimidines, pyrrolopyridine, carboline, pyrrolopyrimidone, and CMPD 1 are assayed for their ability to reduce phosphorylation of the respective MENA isoform substrates using the assays described above. Such methods are well known to those in the art (reviewed by von Ohsen and Bomer, 2005, Wang and Ma, 2015). Libraries of potential kinase inhibitors are commercially available (cf. SYNkinase, Parkville, Victoria, Australia) and screening can be carried out under commercial service (e.g. the KiNativ™ service described in Patricelli, et al., 2011. Inhibitors identified in the assay may be modified by methods well known in the art to optimize their inhibitory characteristics and to improve drugability. Those exhibiting the most advantageous inhibitor profiles are selected for further in vivo testing as described below.

Example 3

(62) Identifying MENA Isoform Kinase Peptide Inhibitors

(63) Peptide MENA isoform kinase inhibitors are identified by use of the same (or similar) panel of in vitro assays as described in Example 1. Peptides comprising SEQ ID Nos.: 14-29 are assayed and those with the best inhibitor profiles selected for further in vivo testing as described in further examples herein.

Example 4

(64) MENA Kinase Inhibitors Reduce Incidence of Metastatic Cancer in an In Vivo PyMT Mouse Model

(65) The ability of the MENA kinase inhibitors to reduce metastasis in the PyMT mouse breast cancer model (described in detail by Harney, et al., 2015) is assayed by administering an effective dose of the inhibitor to a mouse with a previously established xenograft tumor. Appropriate doses of the inhibitor may be determined by methods well known in the art. In these experiments, the baseline level of circulating tumor cells and tumor cell dissemination is established and the MENA kinase inhibitor is then administered to the mouse. Subsequent changes in MetaSites, circulating tumor cell numbers, and lung metastases are monitored. Reduction of levels of number of MetaSites, circulating tumor cells, and lung metastases indicate that the MENA kinase inhibitor reduces cancer metastasis in pre-existing metastatic tumors.

(66) Additional experiments are carried out to determine efficacy of MENA.sup.INV kinase inhibitors to suppress tumor metastasis. These additional experiments involve treatment of the subject mouse with MENA.sup.INV kinase inhibitor prior to introduction of the xenograft tumor and determining MetaSite density and the level of circulating tumor cells through the course of tumor development. Reduction in MetaSite density and tumor cell circulation relative to the baseline numbers established in matched untreated control mice indicates that the MENA.sup.11a kinase inhibitor effectively inhibits establishment of the metastatic phenotype.

Example 5

(67) MENA Kinase Inhibitors Reduce Incidence of Metastatic Cancer in a Mouse Model

(68) The ability of the MENA kinase inhibitors to reduce metastasis in a nod/skid mouse transplanted with a human triple negative breast cancer (TNBC) cell line MDA-MB-231 (described in detail by Odin et al., 2017) is determined. These experiments involve assessing organs upon sacrifice for the presence of metastatic lesions and blood for increase in the number of circulation tumor cells (CTC's). Reduction of levels of circulating tumor cells and lung metastases indicate that the MENA kinase inhibitor reduces cancer metastasis.

Example 6

(69) Combination Treatment with MENA-Kinase Inhibitors and Paclitaxel Restores Paclitaxel Sensitivity and Reduces Paclitaxel-Induced Tumor Cell Dissemination

(70) Cytotoxic chemotherapy, including the use of taxanes, remains the standard of care for treatment of advanced cancer and aggressive cancer such as Triple Negative Breast Cancer (TNBC). Despite the benefits associated with cytotoxic chemotherapy response rates can be low and for example TNBC can become resistant within a year of treatment. Treatment with paclitaxel can also induce tumor cell dissemination. Taxanes such as paclitaxel cause mitotic catastrophe by stabilizing microtubules and inhibiting disassembly during metaphase leading to mitotic arrest and cell death. MENA.sup.INV expression alters the ratio of dynamic and stable microtubule populations in paclitaxel-treated tumor cells. MENA expression also increases MAPK signaling in response to paclitaxel treatment. Decreasing phosphorylation of MENA.sup.INV by co-treatment with MENA kinase inhibitors can restore paclitaxel sensitivity by driving microtubule stabilization.

Example 7

(71) Combination Treatment with MENA Isoform Kinase Inhibitors and Gefitinib Reduces Spontaneous Resistance to Gefitinib

(72) The EGFR specific TKI, gefitinib, is effective in initial treatment of many cancers, particularly non-small-cell lung cancers, but frequently loses efficacy due to compensatory mutations within EGFR or in ancillary receptor pathways [reviewed in Kosaka, et al., 2011]. Other drugs suitable for use in the practice of present invention include but are not limited to: Erbitux® (Cetuximab), Tarceva® (Erlotinb), Iressa® (Gefitinb), Tykerb® (Lapatinib), Cometriq® (Cabozantinib), Xalkori® (Crizotinib), Vectibix® (Panitumumab), and Gioreif® (Afatinib). Drugs which are currently in development which are suitable for use in the practice of present invention include but are not limited to: tivantinib (ARQ97), rilotumumab (AMG 102), AMG479 (IGF-1R inhibitor), AMG 337 (c-MET inhibitor), ficlatuzumab (AV-299), tivantinib (ARQ197) and onartuzumab (c-MET inhibitor). MENA's role in recruiting the PTPlb kinase/dephosphorylase to EGFR [see Hughes, et al., 2015] suggests that the combined effect of modulating the phosphorylation of EGFR directly with gefitinib and indirectly via MENA may reduce the incidence of spontaneous resistance to gefitinib. To test the ability of MENA isoform kinase inhibitors to reduce the incidence of spontaneous resistance to gefitinib, gefitinib and MENA isoform kinase inhibitor are administered to PyMT mouse breast cancer model mice, individually and in combination after establishment of the xenograft tumor as described above. MetaSite density and the level of circulating tumor cells are monitored through the course of tumor development. Significant decreases in overall MetaSite density and circulating tumor cells in the mice receiving both gefitinib and MENA isoform kinase inhibitor, relative to mice receiving gefitinib or the MENA isoform kinase inhibitor alone, indicate that the combination therapy is effective. The kinetics of MetaSite development and observed level of circulating tumor cells provides insight into the ability of the MENA isoform kinase inhibitor to retard development of gefitinib resistance. Significant delays in developing significant MetaSite levels and increased circulating tumor cells in mice receiving the combination therapy relative to mice receiving just gefitinib indicate that the MENA isoform kinase inhibitors suppress development of gefitinib resistance.